NCT03988036
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03988036
Title A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
Acronym Keyriched-1
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors West German Study Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Universitätsklinikum Tübingen Frauenklinik Tübingen Baden-Wurttemberg 72076 Germany Details
Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern Munich Bavaria 80377 Germany Details
Rotkreuzklinikum München GmbH Frauenklinik Munich Bavaria 80637 Germany Details
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg Zentrum für Frauenheilkunde und Abteilung für Senologie Georgsmarienhütte Lower Saxony 49124 Germany Details
Diakoniekrankenhaus Henriettenstiftung GmbH Hanover Lower Saxony 30559 Germany Details
Onkologische Praxis Bielefeld North Rhine-Westphalia 33604 Germany Details
St. Elisabeth Krankenhaus GmbH Brustzentrum Cologne North Rhine-Westphalia 50935 Germany Details
Onkodok GmbH Gütersloh North Rhine-Westphalia 33332 Germany Details
Ev. Krankenhaus Bethesda Brustzentrum Niederrhein Mönchengladbach North Rhine-Westphalia 41061 Germany Details
Praxisnetzwerk Troisdorf North Rhine-Westphalia 53840 Germany Details
Charité Campus Mitte Klinik für Gynäkologie Berlin 10117 Germany Details
Mammazentrum Hamburg Hamburg 20357 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field